• 1
    IARC: GLOBOCAN. Cancer incidence, mortality and prevalence worldwide, 2002. Available at
  • 2
    Zhang L,Conejo-Garcia JR,Katsaros D,Gimotty PA,Massobrio M,Regnani G,Makrigiannakis A,Gray H,Schlienger K,Liebman MN,Rubin SC,Coukos G. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 20313.
  • 3
    Curiel TJ,Coukos G,Zou L,Avarez X,Cheng P,Mottram P,Evdemon-Hogan M,Conejo-Garcia JR,Zhang L,Burrow M,Zhu Y,Wei S, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 9429.
  • 4
    Marth C,Fiegl H,Zeimet AG,Müller-Holzner E,Deibl M,Doppler W,Daxenbichler G. Interferon-gamma expression is an independent prognostic factor in ovarian cancer. Am J Obstet Gynecol 2004; 191: 1598605.
  • 5
    Pujade-Lauraine E,Guastalla JP,Colombo N,Devillier P,François E,Fumoleau P,Monnier A,Nooy M,Mignot L,Bugat R,Marques C,Mousseau M, et al. Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy. J Clin Oncol 1996; 14: 34350.
  • 6
    Windbichler GH,Hausmaninger H,Stummvoll W,Graf AH,Kainz C,Lahodny J,Denison U,Müller-Holzner E,Marth C. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 2000; 82: 113844.
  • 7
    Alberts DS,Marth C,Alvarez RD,Johnson G,Bidzinski M,Kardatzke DR,Bradford WZ,Loutit J,Kirn DH,Clouser MC,Markman M. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol 2008; 109: 17481.
  • 8
    Tanaka N,Taniguchi T. The interferon regulatory factors and oncogenesis. Semin Cancer Biol 2000; 10: 7381.
  • 9
    Taniguchi T,Ogasawara K,Takaoka A,Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001; 19: 62355.
  • 10
    Harada H,Kitagawa M,Tanaka N,Yamamoto H,Harada K,Ishihara M,Taniguchi T. Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science 1993; 259: 9714.
  • 11
    Lowney JK,Boucher LD,Swanson PE,Doherty GM. Interferon regulatory factor-1 and -2 expression in human melanoma specimens. Ann Surg Oncol 1999; 6: 6048.
  • 12
    Connett JM,Badri L,Giordano TJ,Connett WC,Doherty GM. Interferon regulatory factor 1 (IRF-1) and IRF-2 expression in breast cancer tissue microarrays. J Interferon Cytokine Res 2005; 25: 58794.
  • 13
    Kim EJ,Lee JM,Namkoong SE,Um SJ,Park JS. Interferon regulatory factor-1 mediates interferon-gamma-induced apoptosis in ovarian carcinoma cells. J Cell Biochem 2002; 85: 36980.
  • 14
    Zeimet AG,Marth C,Offner FA,Obrist P,Uhl-Steidl M,Feichtinger H,Stadlmann S,Daxenbichler G,Dapunt O. Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol 1996; 62: 3849.
  • 15
    Siemens CH,Auersperg N. Serial propagation of human ovarian surface epithelium in tissue culture. J Cell Physiol 1988; 134: 34756.
  • 16
    Wang Y,Liu DP,Chen PP,Koeffler HP,Tong XJ,Xie D. Involvement of IFN regulatory factor (IRF)-1 and IRF-2 in the formation and progression of human esophageal cancers. Cancer Res 2007; 67: 253549.
  • 17
    Vaughan PS,van der Meijden CMV,Aziz F,Harada H,Taniguchi T,van Wijnen AJ,Stein JL,Stein GS. Cell cycle regulation of histone H4 gene transcription requires the oncogenic factor IRF-2. J Biol Chem 1998; 273: 1949.
  • 18
    Yoshino A,Katayama Y,Yokoyama T,Watanabe T,Ogino A,Ota T,Komine C,Fukushima T,Kusama K. Therapeutic implications of interferon regulatory factor (IRF)-1 and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to interferon (IFN)-beta in glioblastoma cells and prognostic value for DIA. J Neurooncol 2005; 74: 24960.
  • 19
    Doherty GM,Boucher L,Sorenson K,Lowney J. Interferon regulatory factor expression in human breast cancer. Ann Surg 2001; 233: 6239.
  • 20
    Berchuck A,Iversen ES,Lancaster JM,Dressman HK,West M,Nevins JR,Marks JR. Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 2004; 190: 91025.
  • 21
    Zeimet AG,Widschwendter M,Knabbe C,Fuchs D,Herold M,Müller-Holzner E,Daxenbichler G,Offner FA,Dapunt O,Marth C. Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol 1998; 16: 18618.
  • 22
    Wolf D,Wolf AM,Rumpold H,Fiegl H,Zeimet AG,Muller-Holzner E,Deibl M,Gastl G,Gunsilius E,Marth C. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005; 11: 832631.
  • 23
    Mori K,Stone S,Khaodhiar L,Braverman LE,DeVito WJ. Induction of transcription factor interferon regulatory factor-1 by interferon-gamma (IFN gamma) and tumor necrosis factor-alpha (TNF alpha) in FRTL-5 cells. J Cell Biochem 1999; 74: 2119.
  • 24
    Geller DA,Nguyen D,Shapiro RA,Nussler A,Di Silvio M,Freeswick P,Wang SC,Tweardy DJ,Simmons RL,Billiar TR. Cytokine induction of interferon regulatory factor-1 in hepatocytes. Surgery 1993; 114: 23542.